News

Wednesday
Jan272016

Innovation Foundation Grant

MinervaX announces that the company has been awarded a grant worth DKK 4.5 million (EUR 0.6 million) from the Danish Innovation Foundation, under the Innobooster Programme, for the development of its Group B Streptococcal Vaccine.

Wednesday
Nov042015

Initiation of Phase I Part B

MinervaX announces that it today has dosed the first subject in it Phase I Part B Dose-confirmation trial on its Group B Streptococcal vaccine GBS-NN, due to enrol 240 healthy adult women.

Wednesday
Oct282015

Participation in Bill & Melinda Gates Foundation Grant

MinervaX announces that the company is a participant in a BMGF grant worth USD 0.5 million awarded to Professor Sharbir Madhi, South Africa for studies on correlates of protection focusing on naturally occurring antibodies directed at the company’s vaccine antigens. Co.applicatant of the grant is also Professor Bengt Johansson-Lindbom, Lund University, Sweden.

Tuesday
Jun022015

Initiation of Phase I clinical trial

MinervaX announced today that the company has initiated a Phase I clinical trial for its GBS vaccine candidate GBS-NN. The Phase I trial will enrol up to 310 healthy adult women in two parts, Part A, which is a safety and dose-escalation trial in up to 70 women, and Part B, which is an extended safety and dose confirmation trial in up to 240 women.

Press release
Statement from Professor Paul Heath, UK
Statement from Group B Strep Association, US
Wednesday
Jan082014

Equity and Loan Financing

MinervaX announces that the company has raised DKK 22 million (EUR 3 million) for the development of its Group B Streptococcal Vaccine. The financing was a combination of an equity financing led by Novo Seeds, the seed arm of Novo A/S, supported by Sunstone Capital and LF Investment, and a Syndication Loan from The Danish Growth Foundation (VækstFonden).

Press release